The company had released trial data on Monday that showed its experimental vaccine prevented on average 70% of COVID-19 cases in late-stage trials in Britain and Brazil. They have fallen about 7% since it reported the vaccine data on Monday. Moderna shares have rallied 22% since it released its trial data on Nov. 16, while Pfizer and BioNTech are up 6% and 14% respectively since announcing data on Nov. 9. The US Food and Drug Administration (FDA), has not commented on the trial results. The European Medicines Agency said on Thursday it would "assess data on the efficacy and safety of the vaccine in the coming weeks".

Source: bd News24 November 27, 2020 13:41 UTC